Short Summary
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
Detailed Summary
In a Final Written Decision on Remand, the Patent Trial and Appeal Board affirmed Apple’s challenge to Omni MedSci’s U.S. Patent No. 10,517,484 covering a wearable device for measuring blood oxygen saturation. After the Federal Circuit affirmed the Board’s construction of the term “identify an object,” the Board considered Apple’s alternative argument and concluded that a person of ordinary skill would have been motivated to combine the teachings of Lisogurski, Carlson, Tran, Isaacson, and Valencell‑093, rendering all 23 claims obvious under 35 U.S.C. §103. Consequently, the Board ordered that claims 1–23 are unpatentable, confirming earlier findings for claims 1,2,7,15‑23 and extending unpatentability to the remaining claims.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAMSUNG ELECTRONICS CO., LTD. et al. vs OMNI MEDSCI, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
PacifiCorp et al.vsMES, Inc.
The PTAB institution decision found that the Petitioner successfully established a reasonable likelihood of prevailing on multiple claims against Birchtech Corp.'s patent. The grounds for unpatentability centered on obviousness (103) based on combining prior art related to pollutant removal from flue gas.
Samsung Electronics Co., Ltd. et al.vsAdvanced Coding Technologies, LLC
Samsung and Advanced Coding Technologies settled their IPR dispute over patent 8,090,025, leading the PTAB to terminate the proceeding. The settlement agreement was treated as confidential business information.
Fortinet, Inc.vsNetskope, Inc.
Fortinet has filed an IPR petition challenging all 35 claims of Netskope’s ’282 patent covering dynamic firewall rule updates, asserting anticipation and obviousness over the Coss patent and the Ke publication.
Ebury Partners UK Ltd.vs--
Ebury Partners UK Ltd. and Intercurrency Software LLC entered into a settlement that grants Ebury a royalty‑free license to several patents covering cross‑border payments, includes covenants not to sue, and mandates dismissal of the pending IPR and related lawsuit.
Honeywell International Inc.vsDSM IP Assets, B.V. et al.
Honeywell seeks Director review of the PTAB’s denial of institution of its IPR against DSM’s colored‑suture patent. The petitioner contends the Board erred on patentable weight, combination rewriting, obvious‑to‑try analysis, and reasonable‑expectation‑of‑success standards. The request argues that the prior art makes the claims obvious and unpatentable.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.